Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical oncologists have numerous treatment options for their metastatic colorectal cancer patients, and are looking to optimize the sequencing of these therapies in a way that will lead to the maximal outcome for patients and make the most efficient use of available funds.
Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer
This Unmet Need report focuses on the treatment of previously treated RAS and BRAF mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...
Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
Targeted therapies and various biomarkers (e.g., RAS,
Colorectal Cancer - Epidemiology - Mature Markets
DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of col...
Colorectal Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are